NCT05970536

Brief Summary

This clinical trial is designed to study and compare the effect of two different types of chelating agents on the vital pulp therapy of mature permanent teeth with irreversible pulpitis using bioceramic material.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2022

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 8, 2023

Completed
24 days until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

April 18, 2024

Status Verified

July 1, 2023

Enrollment Period

1 year

First QC Date

July 8, 2023

Last Update Submit

April 17, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Success rate of vital pulp therapy of mature permanent teeth with irreversible pulpitis using bioceramic material.

    1. Through post operative pain assessment using Visual analogue scale (0-3) scores as 0 represents no pain, 1= mild pain, 2= moderate pain and 3= sever pain. VAS scores marked at intervals of 2,6,24,48 and 72 hours. 2. Clinical success criteria: Clinical parameters indicating successful treatment include the following criteria: * Absence of pain except for the first 24 hours. * Normal soft tissue around the tooth ( no swelling, no sinus tract).

    one year

  • The Pulp vitality

    Pulp vitality will be assessed through pulpal response to thermal and electrical pulp tests. at 3,6,12 months

    one year

Secondary Outcomes (1)

  • Radiographic success

    one year

Study Arms (2)

Apple vinegar group

EXPERIMENTAL

After hemostasis of the exposed pulp is achieved, Apple vinegar will be used for dentin conditioning for 5 mins then 1-2 mm thickness of MTA placed on the exposed pulp chamber.

Other: Apple vinegar or EDTA 17%

EDTA 17% group

ACTIVE COMPARATOR

After hemostasis of the exposed pulp is achieved, EDTA 17 % will be used for dentin conditioning then 1-2 mm thickness of MTA placed on the exposed pulp chamber.

Other: Apple vinegar or EDTA 17%

Interventions

Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.

Apple vinegar groupEDTA 17% group

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Presence of at least one tooth with carious pulp exposure and irreversible pulpitis.
  • Cooperative behavior with no medical problem.
  • Absence of tooth mobility , tenderness on percussion.
  • History of pain with cold and sweets.
  • Radiographically, no internal or external resorption, no periapical or furcation radiolucency and no widening of the periodontal membrane space.

You may not qualify if:

  • Teeth with pulp necrosis.
  • Presence of sinus tract.
  • Teeth with open apices.
  • Pregnant women.
  • History of intolerance of non- steroidal anti inflammatory drugs.
  • Tenderness to palpation of adjacent soft tissues

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mona Rizk Abo El Wafa Ahmed

Cairo, Egypt

Location

Related Publications (1)

  • Sobh YTM, Ahmed MRA. The effect of two different contemporary chelating agents on vital pulp therapy in mature permanent teeth with irreversible pulpitis using bioceramic material: randomized clinical trial. BMC Oral Health. 2024 Aug 8;24(1):918. doi: 10.1186/s12903-024-04627-6.

Study Officials

  • Mona R Abo El Wafa Ahmed, PhD

    Faculty of Dentistry, Sinai University.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
double ( participant, outcome assessor)
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel double blinded.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

July 8, 2023

First Posted

August 1, 2023

Study Start

December 1, 2022

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

April 18, 2024

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL
Time Frame
2 years

Locations